- Details
- Christopher Evans, Professor and Chair, Department of Urologic Surgery at UC-Davis discussed the management of men with PSA recurrence or persistence after radical prostatectomy during the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 session on PSA recurrence after radical local therapy and oligometastatic prostate cancer. He followed Dr. Felix Feng's presentation on PSA Recurrence a...
|
- Details
- Felix Feng presented during the PSA Recurrence after Radical Local Therapy and Oligometastatic Prostate Cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). He focused on the topic of management of men with PSA recurrence after radical local radiation therapy. Of the 1.2 million-plus patients that are diagnosed with prostate cancer each year worldwide, in the United St...
|
- Details
- At the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Dr. Alicia Morgans presented on disparities in prostate cancer management in the United States. Dr. Morgans highlights the 174,650 new cases of prostate cancer in the United States in 2019 and noting that social health is determined by many factors which could be responsible for these disparities, she frames her discussion around wh...
|
- Details
- In this presentation by Fernando Maluf at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) he summarizes the results of the first Latin American Oncology Group (LACOG) consensus conference, a Cooperative Group Consensus that takes place in Brazil, a consensus conference for developing countries. This unique conference provided guidelines for prostate cancer, specifically for areas of...
|
- Details
- At the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) Darren Poon gave an overview of prostate cancer in the East-Asian ethnicity. This ethnicity includes China, (including Hong-Kong and Macau), Japan, Mongolia, North Korea, South Korea, and Taiwan. When assessing the taxane related adverse events in Asian prostate cancer patients, compared to the rates described in the major studies,...
|
- Details
- Colin Pritchard opens the first session on Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer at the APCCC 2019 with the presentation, The State of the Art on Molecular Characterization of Advanced Prostate Cancer Presentation. Biography: Colin C Pritchard, M.D., Ph.D. is the director of the Genetics and Solid Tumors Laboratory at University Washington Medical Center, as well as a...
|
- Details
- Professor de Bono presents the clinical utility of predictive molecular biomarkers in advanced prostate cancer during the first session of the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Biographies: Johann de Bono, MB ChB FRCP MSc Ph.D. FMedSci. Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cance...
|
- Details
- In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, mo...
|
